Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score.

Journal: Frontiers in immunology
PMID: 38863693

Abstract

INTRODUCTION: This study aimed to develop a prognostic nomogram for predicting the recurrence-free survival (RFS) of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients with low preoperative platelet-albumin-bilirubin (PALBI) scores after transarterial chemoembolization (TACE) combined with local ablation treatment.

Authors

  • Qi Wang
    Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Shugui Sheng
    Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Yiqi Xiong
    Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
  • Ming Han
    James Franck Institute, University of Chicago, Chicago, IL 60637.
  • Ronghua Jin
    National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
  • Caixia Hu
    Beijing Aerospace Automatic Control Institute, Beijing 100000, China.

Keywords

External Resources

Popular Topics
Recent Journals